Abba Medix Corp. Announces Supply Agreement with Alberta Gaming, Liquor and Cannabis

Published: February 11, 2020

Abba Medix Corp. Announces Supply Agreement with Alberta Gaming, Liquor and Cannabis

Canada House Wellness Group Inc. announced that its wholly owned subsidiary, Abba Medix Corp. (“Abba“), has entered into a supply agreement with Alberta Gaming, Liquor and Cannabis (“AGLC“) for the supply of branded cannabis products to the adult-use market in the Province of Alberta.  Under the supply agreement, Abba will initially offer recreational use products in 3.5-gram dried flower and 0.5-gram pre-rolled formats.  Abba continues to be engaged in advanced discussions with other provincial cannabis distribution branches as it executes its domestic distribution strategy.

“We are delighted to announce our relationship with AGLC and look forward to selling our trusted, medical-grade cannabis strains to Alberta recreational consumers,” said Chris Churchill-Smith, Chief Executive Officer of Canada House. “This supply agreement is a significant milestone on Canada House’s Path to Profitability. We will continue to pursue additional provincial supply agreements with targeted provinces at optimal price points, building on Abba’s European export strategy and existing revenue from our broad medical patient base.”

“This milestone is a testament to the hard work, dedication, and commitment of all Abba employees to growing and sourcing top-notch cannabis that is sought after in the medical and recreational markets,” added Michael Orrbrooke, President of Abba and the Chief Revenue Officer of Canada House. “Our products have received great reviews from our medical patient base, and we are excited to share these products with Alberta recreational consumers.”

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article